by Truveta staff | Apr 21, 2026 | Research
Authors: Wilson Lau ⊕Truveta, Inc, Bellevue, WA, Youngwon Kim ⊕Truveta, Inc, Bellevue, WA, Sravanthi Parasa ⊕Swedish Medical Center, Seattle, WA, Md Enamul Haque ⊕Truveta, Inc, Bellevue, WA, Anand Oka ⊕Truveta, Inc, Bellevue, WA, Jay Nanduri ⊕Truveta, Inc, Bellevue,...
by Truveta Research | Apr 20, 2026 | Research
Nearly 8% of all prescriptions in March 2026 were for GLP-1 RAs, following the largest quarter-over-quarter percentage point increase in overall GLP-1 RA prescribing observed since the study began in 2019. First-time anti-obesity medication (AOM) prescribing increased...
by Truveta Research | Apr 14, 2026 | Research
Authors: Karen G Farrar ⊕University of Southern California, Los Angeles, CA, Duy Do ⊕Truveta, Inc, Bellevue, WA, Nina B Masters ⊕Truveta, Inc, Bellevue, WA, Brianna M Cartwright ⊕Truveta, Inc, Bellevue, WA After CVS Caremark made anti-obesity semaglutide the preferred...
by Truveta Research | Apr 14, 2026 | Research
Authors: Brianna M Cartwright ⊕Truveta, Inc, Bellevue, WA, Duy Do ⊕Truveta, Inc, Bellevue, WA, Jennifer J Liang ⊕Truveta, Inc, Bellevue, WA, Natasha Geogy ⊕Truveta, Inc, Bellevue, WA, Nina B Masters ⊕Truveta, Inc, Bellevue, WA, Karen G Farrar ⊕Truveta, Inc, Bellevue,...
by Truveta Research | Apr 9, 2026 | Research
Estrogen-based hormone replacement therapy (HRT) prescribing more than doubled from 2018 to 2026. The largest increases were seen in patches and vaginal creams, with patch use more than tripling and vaginal cream use increasing more than fourfold. The rates of women...
by Truveta staff | Apr 7, 2026 | Research
Four studies using Truveta Data examined real-world outcomes across diverse urology populations, spanning medical therapy, stone disease, oncology, and men’s health. The analyses identified differences in treatment patterns, safety, and outcomes not captured in...
